Physician profile
Charles A Sever
NPI 1952306847
$9,994.51
in general payments reported to CMS, 2019-2025
24 companies · $2,470 in 2025
The $2,470 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $587 · 2022: $534 · 2023: $2,226 · 2024: $4,178 · 2025: $2,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,998 · Travel and Lodging: $3,830 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,998.34 |
| Travel and Lodging | $3,830.14 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Saluda Medical Americas, INC. | $4,083.86 | 2023-2025 | Evoke, Evoke Scs |
| Medtronic, INC. | $2,630.24 | 2022-2025 | Synchromedii, Inceptiv, Intellis Adaptivestim |
| Relievant Medsystems, INC. | $1,257.82 | 2023 | Intracept |
| Abbott Laboratories | $483.25 | 2021-2025 | Proclaim |
| Grt US Holding, INC. | $243.76 | 2021-2022 | |
| Spr Therapeutics, INC | $215.89 | 2022-2025 | Sprint Pns System |
| Averitas Pharma INC. | $175.63 | 2023-2025 | Qutenza |
| Abbvie INC. | $129.91 | 2023-2025 | |
| Collegium Pharmaceutical, INC. | $111.13 | 2021-2023 | Belbuca |
| Pacira Pharmaceuticals Incorporated | $106.45 | 2023 | Iovera |
| Amgen INC. | $72.43 | 2021-2025 | Evenity, Prolia, Prolia |
| Nevro Corp. | $65.47 | 2022-2023 | Senza |
| Almatica Pharma LLC | $63.20 | 2021-2022 | |
| Ucb, INC. | $54.89 | 2022 | |
| Arbor Pharmaceuticals, INC. | $54.63 | 2021 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pacira Therapeutics, INC. | $52.66 | 2021 | |
| Radius Health, INC. | $43.92 | 2021-2022 | |
| Boston Scientific Corporation | $37.24 | 2022-2025 | Intracept |
| Takeda Pharmaceuticals U.S.A., INC. | $24.58 | 2024 | Trintellix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $20.60 | 2023 | Jardiance |
| Si-Bone, INC. | $20.04 | 2021 | |
| Novo Nordisk INC | $17.26 | 2024 | Ozempic, Rybelsus |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $17.12 | 2023 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $12.53 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Sever listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.